TCF25 Orchestrates Lysosomal Cell Death in Glucose Starvation

Study Background and Research Question

Cellular response to nutrient deprivation is a fundamental process in physiology and disease. Glucose, the primary carbon source for energy production and biosynthesis, is tightly regulated by multiple adaptive mechanisms. Under glucose starvation, cells activate pathways such as AMP-activated protein kinase (AMPK) and autophagy to sustain ATP levels and maintain cellular function. However, prolonged deprivation often leads to cell death, contributing to tissue injury in conditions such as ischemia-reperfusion injury (IRI). Precisely how cells orchestrate the balance between adaptive survival and commitment to death during metabolic stress remains incompletely understood. The recent work by Ren et al. (2025) addresses this critical gap, focusing on the transcription factor TCF25 as a central regulator of lysosomal function and cell fate under glucose starvation.

Key Innovation from the Reference Study

The central innovation of Ren et al. lies in identifying TCF25 as a nutrient sensor that governs both metabolic adaptation and lysosome-dependent cell death (LDCD) during glucose deprivation. Through a genome-wide CRISPR-Cas9 screen, the authors reveal TCF25 as essential for cell death induced by glucose starvation, linking it mechanistically to the regulation of lysosomal acidification via V-ATPase and the induction of ferritinophagy. This dual role places TCF25 at the intersection of energy conservation, iron metabolism, and regulated cell death, offering a new conceptual framework for understanding how cells transition from survival to death under metabolic stress (Ren et al., 2025).

Methods and Experimental Design Insights

To interrogate the molecular underpinnings of glucose-starvation-induced cell death, Ren et al. employed a genome-wide CRISPR-Cas9 knockout screen in cultured mammalian cells. This unbiased approach allowed the identification of genes whose loss confers resistance to cell death under glucose deprivation. Enrichment analysis of the screen hits highlighted lysosomal pathway components, with TCF25 emerging as a top candidate. Functional validation included genetic knockout and overexpression of TCF25, assessment of lysosomal acidification using pH-sensitive dyes, and monitoring of autophagic flux. Ferritinophagy was evaluated by tracking ferritin degradation and iron release, while involvement of V-ATPase was probed using both genetic and pharmacological inhibition. In vivo relevance was established in mouse models of hepatic ischemia-reperfusion injury, using TCF25-deficient animals to assess tissue protection and cell death outcomes under metabolic stress.

Core Findings and Why They Matter

The study's core findings are summarized as follows:

• TCF25 is critical for cell death under glucose starvation: Loss of TCF25 confers resistance to glucose-starvation-induced cell death in vitro and protects against hepatic IRI in vivo (Ren et al., 2025).
• Enhancement of lysosomal acidification via V-ATPase: TCF25 upregulates V-ATPase activity, leading to increased lysosomal acidification during glucose deprivation. This is essential for sustaining autophagy and energy homeostasis in the early phase of starvation.
• TCF25-mediated ferritinophagy triggers lysosome-dependent cell death: Under prolonged glucose deprivation, TCF25 promotes ferritin degradation (ferritinophagy), leading to iron release within lysosomes. This increases lysosomal membrane permeability (LMP) and triggers cell death through the LDCD pathway.
• Potential for therapeutic targeting: Inhibition of TCF25 or V-ATPase components prevents cell death, while TCF25 deficiency protects against tissue injury, highlighting new avenues for intervention in metabolic and ischemic pathologies.

These findings underscore the pivotal role of lysosomal iron handling in cellular fate decisions and link nutrient sensing to regulated cell death via previously unappreciated mechanisms. The work also suggests that manipulating iron metabolism and lysosomal activity could be a generalizable strategy across cancer and degenerative disease contexts.

Comparison with Existing Internal Articles

Ren et al.'s mechanistic insights bridge nutrient sensing, iron metabolism, and cell death, complementing recent literature on iron chelation strategies in cancer and metabolic disease. For example, internal articles such as "Deferasirox: Advancing Iron Chelation Therapy and Metabolic Modulation" highlight how oral iron chelators not only treat iron overload but can modulate metabolic and apoptotic pathways relevant to tumor suppression. Similarly, "TCF25 Links Glucose Starvation to Lysosomal Cell Death via Acidification" summarizes how TCF25-driven acidification and ferritinophagy contribute to cell death modalities of interest in both oncology and tissue injury. These resources collectively emphasize the translational potential of targeting iron metabolism and lysosomal pathways, as exemplified by both TCF25 mechanistic studies and the experimental use of iron chelators in preclinical models.

Moreover, investigations into Deferasirox as an oral iron chelator have demonstrated its ability to inhibit tumor growth, induce apoptosis via caspase-3 activation, and impede iron uptake from transferrin, supporting its consideration as both a research tool and therapeutic candidate in the context of metabolic and cell death pathways influenced by iron availability (related review).

Limitations and Transferability

While the study by Ren et al. provides compelling evidence for TCF25 as a nutrient sensor and mediator of lysosomal cell death, several limitations warrant attention. Most experiments were conducted in vitro or in murine models, and the direct relevance to human pathologies, especially chronic disease states, requires further validation. The generalizability of TCF25’s role across different cell types and tissues under variable metabolic conditions is not fully established. In addition, the interplay between TCF25-mediated pathways and other regulators of iron metabolism—such as those targeted by oral iron chelators in cancer treatment—remains an open area for integrative study.

Researchers should also consider the context-dependent effects of modulating lysosomal function and iron homeostasis, as interventions may carry risks of off-target effects or altered cell fate in non-target tissues. Careful titration of iron chelation, for example, is essential to avoid unwanted cytotoxicity or impairment of normal cellular processes.

Protocol Parameters

• Glucose starvation induction: Typically performed by culturing cells in glucose-free medium for defined durations (e.g., 12–48 hours), with monitoring of viability and autophagic markers.
• Assessment of lysosomal acidification: Employ pH-sensitive fluorescent dyes (e.g., LysoSensor) and quantification of V-ATPase activity following TCF25 manipulation.
• Ferritinophagy measurement: Track ferritin degradation via immunoblotting and assess lysosomal iron content using iron-sensitive probes.
• Gene knockout/overexpression: Use CRISPR-Cas9 or lentiviral expression systems to modulate TCF25 and V-ATPase subunits in relevant cell lines.
• Cell death quantification: Employ assays for lysosomal membrane permeability (e.g., acridine orange relocation), caspase activation, and viability (e.g., Annexin V/PI staining).
• Iron chelator intervention (e.g., Deferasirox): Apply at concentrations of 3–20 μM in vitro, as reported in the product information, to investigate effects on iron-dependent cell death pathways.

Research Support Resources

For researchers aiming to study iron metabolism, cell death, or metabolic adaptation under nutrient stress, validated reagents and workflow-compatible compounds are essential. Deferasirox (SKU A8639) is a widely used oral iron chelator with well-characterized effects on iron uptake inhibition, apoptosis induction, and modulation of mitochondrial ROS. Its established protocols and safety profile make it suitable for in vitro and in vivo studies modeling iron-dependent cell death, ferritinophagy, and related metabolic pathways. Deferasirox is available from APExBIO for experimental use; see the product page for detailed specifications and storage guidelines.